Granulocyte-Colony Stimulating Factor (G-CSF) May Improve Disease Outcome in Elderly Patients with Diffuse Large Cell Lymphoma (DLCL) Treated with CHOP Chemotherapy

References

• Bloomfield CD, Goldman A, Dick F. Multivariate analysis of prognostic factors in the non-Hodgkin's malignant lymphomas. Cancer 1971; 33: 870–879
   Web of Science ®Google Scholar
• Fisher RI, DeVita T, Johnson BL. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J Med 1977; 63: 177–182
   PubMed Web of Science ®Google Scholar
• Cabanillas F, Burke JS, Smith TL. Factors predicting for response and survival in adults with advanced non-Hodgkin's lymphoma. Arch Int Med 1978; 138: 413–418
   PubMed Web of Science ®Google Scholar
• Fisher RI, Hubbard SM, DeVita VT. Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood 1981; 58: 45–51
   PubMed Web of Science ®Google Scholar
• Koziner B, Little C., Passe S. Treatment of advanced diffuse histiocytic lymphoma: An analysis of prognostic variables. Cancer 1982; 49: 1571–1579
   PubMedGoogle Scholar
• Armitage JO, Dick FR, Corder MP. Predicting therapeutic outcomes in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP). Cancer 1982; 50: 1695–1702
   Google Scholar
• Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma: Increased complications with advancing age. J Am Geriatr Soc 1984; 32: 269–273
   PubMed Web of Science ®Google Scholar
• Dixon DO, Neilan B, Jones SE. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986; 4: 295–305
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Chastang Cherrara A. Age as the man prognostic factor in adult aggressive non-Hodgkin's lymphoma. Am J Med 1987; 83: 1075–1079
   PubMed Web of Science ®Google Scholar
• Vose JM, Armitage JO, Weisenburger DD. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1838–1844
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–94
   Google Scholar
• Holmes FF. Clinical evidence for change in tumor aggressiveness with age. Geriatric Oncology, L. Balducci, G.H. Lyman, W.B. Ershler. Lippincott, Philadelphia, PA 1992; 86–91
   Google Scholar
• Repetto L, Vercelli M, Simoni C. Comorbid conditions among elderly cancer patients. Ann Oncol 1994; 5, (suppl 8), 0288
   Google Scholar
• Balducci L, Parker M, Sexton W, Tantranond P. Pharmacology of antineoplastic agents in the elderly patient. Semin Oncol 1989; 16: 76–84
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Sonneveld P, de Ridder M, van der Lelie H. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995; 13: 2530–2539
   PubMed Web of Science ®Google Scholar
• Meyer R, Browman G, Samosh M. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 2386–2393
   PubMed Web of Science ®Google Scholar
• Tirelli U, Errante D, Van Glabbeke M. CHOP is the standard regimen in patients ∼ 70 years of age with intermediate-grand and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16: 27–34
   PubMed Web of Science ®Google Scholar
• Kwak L, Halpern J, Olshen R, Horning S. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 1990; 8: 963–977
   PubMed Web of Science ®Google Scholar
• Bennett CL, Somerfield MR, Feinglass J, Smith TJ. Decrease in misuse/overuse of hematopoietic colony stimulating factors (CSFs) for solid tumors and lymphomas: results from ASCO surveys related to the 1994 and 1996 ASCO CSF guidelines. Proc ASCO 1998; 17, 1625(abstr)
   Google Scholar
• Aviles A, Diaz-Maqueo Talavera A. Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy. Leuk Lymph 1994; 15: 153–157
   PubMed Web of Science ®Google Scholar
• Pettengell R, Gurney H, Radford JA. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 1992; 80: 1430–1436
   PubMed Web of Science ®Google Scholar
• Balzarotti M, Tondini C., Zanini M. Dose intensification of CHOP in non-Hodgkin's lymphoma (NHL) Final results of a dose-finding study. Proc ASCO 1997; 16, 76 (abstr)
   Google Scholar
• Donnelly GB, Glassman J, Long C. Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with large cell lymphoma (LCL) treated with CHOP. Blood 1998; 92, 2564(abstr)
   Google Scholar
• O'Brien JP, O'Keefe P, Alvarez A. The NHL-15 protocol for diffuse aggressive lymphomas: Two year median follow up on the first 100 patients. Proc ASCO 1995; 14, 1230, (abstr)
   Google Scholar
• ASCO CSF guidelines. J Clin Oncol 1996; 14: 1957–1960
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244–1250
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. JASA 1958; 53: 457
   Web of Science ®Google Scholar
• SAS Institute Inc. SAS/STAT User's Guide, Version 6, Volume 1989; 2, Chapter 26. Cary, NC
   Google Scholar
• Jacobson JO, Grossbard M, Shulman LN. CHOP chemotherapy with G-CSF in elderly patients with intermediate grade lymphoma (IGL) Full dose intensity is possible. Proc ASCO 1998; 17, 41(abstr)
   Google Scholar
• Gomez H, Mas L, Casanova L. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte- macrophage-colony-stimulating factor: Identification of two age subgroups with difference hematologic toxicity. J Clin Oncol 1998; 16: 2352–2358
   PubMed Web of Science ®Google Scholar
• Guerci A., Lederin P, Reyes F. Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen. Ann Oncol 1996; 7: 966–969
   PubMed Web of Science ®Google Scholar
• Gomez H, Hidalgo M, Casanova L. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: Results of a multivariate analysis. J Clin Oncol 1998; 16: 2065–2069
   PubMed Web of Science ®Google Scholar